Jiangxi Qingfeng Pharma 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   1 Trial   1 News 


12»
  • ||||||||||  GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
    Trial completion, Trial completion date, Trial primary completion date:  GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (clinicaltrials.gov) -  Nov 15, 2023   
    P1,  N=24, Completed, 
    The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions. Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Aug 2023
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Retrospective data, Journal:  Network Meta-analysis of different Chinese medicine injections combined with conventional therapy in treatment of stroke-associated pneumonia (Pubmed Central) -  Dec 7, 2022   
    The clinical efficacy of Tanreqing Injection, Xuebijing Injection, Xiyanping Injection, Xingnaojing Injection, Shenmai Injection, or Shenfu Injection combined with conventional therapy was superior to that of conventional therapy alone. However, due to the limitations of the quality and methodology of different intervention measures, this conclusion needs to be verified by more high-quality and rigorously designed randomized controlled trial.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Preclinical, Journal:  Mitochondrial toxicity evaluation of traditional Chinese medicine injections with a dual in vitro approach. (Pubmed Central) -  Nov 22, 2022   
    Furthermore, we identified scutellarin, rutin, phillyrin, and baicalin could be the potential mitochondrial toxic ingredients in the 4 TCM injections by combining molecular docking analysis with experimental validation. Collectively, the dual in vitro approach is worth applying to the safety evaluation of more TCM products, and mitochondrial toxic TCM injections and ingredients found in this study deserve more attention.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Clinical, Retrospective data, Journal:  Network Meta-analysis of heat-clearing and detoxifying Chinese medicine injections in treatment of acute exacerbation of chronic obstructive pulmonary disease (Pubmed Central) -  Jun 22, 2022   
    According to the statistical difference and network Meta-analysis, the injections are in the order of(1)Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in improving the effective rate,(2)Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in decreasing C-reactive protein(CRP),(3)Reduning Injection+conventional western medicine>Xiyanping Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in reducing white blood cell count(WBC),(4)Yuxingcao Injection+conventional western medicine>Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in lowering partial pressure of carbon dioxide(PaCO_2),(5)Yuxingcao Injection+conventional western medicine>Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine>Xiyanping Injection+conventional western medicine in improving partial pressure of oxygen(PaO_2), and(6)Qingkailing Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in shortening mean hospital stay...Among them, Reduning Injection+conventional western medicine and Tanreqing Injection+conventional western medicine demonstrate better and more effects. Due to the differences in the quantity and quality of included studies, the conclusion needs to be further verified.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Retrospective data, Review:  Comparative Efficacy of Chinese Herbal Injections for Septic Shock: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  Apr 26, 2022   
    Regarding procalcitonin level at 7-days, SF + WM, SM + WM, and Xiyanping injection (XYP)+WM were better than WM; XYP + WM was superior for SF + WM, SGM + WM, SM + WM, Danshen injection (DS)+WM, and XBJ + WM; XYP + WM ranked first...More and better evidence is needed to validate the conclusions. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?, identifier CRD42021282958.
  • ||||||||||  GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
    Trial completion, Trial completion date, Trial primary completion date:  A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (clinicaltrials.gov) -  Dec 10, 2021   
    P1,  N=6, Completed, 
    On the basis of this data, patients and clinicians can take precautions to avoid potential drug-interaction risks in COVID-19 treatment. Not yet recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2021 | Trial primary completion date: Mar 2022 --> Nov 2021
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Clinical, Review, Journal:  Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines. (Pubmed Central) -  Sep 21, 2021   
    Findings from clinical studies and Chinese experience in using these CPMs showed that CPMs, when used in combination with conventional treatments, were effective in managing COVID-19 with few side effects. CPMs have excellent efficacy in managing COVID-19 with a great potential for clinical use.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Clinical, Retrospective data, Journal:  Bayesian network Meta-analysis of traditional Chinese medicine injections combined with antiviral western medicine in treatment of influenza (Pubmed Central) -  Sep 2, 2021   
    A total of 49 literatures about 5 061 cases were included finally, involving six traditional Chinese medicine injections, namely Reduning Injection, Xiyanping Injection, Tanreqing Injection, Yanhuning Injection, Qingkailing Injection and Shuanghuanglian Injection...Because of the small quantity and low quality of included studies, the results of this study shall be regarded cautiously and comprehensively. In the future, multi-center, large-sample and clinical randomized controlled trials shall be conducted to verify the results.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Retrospective data, Journal:  Efficacy of Chinese Herbal Injections for Elderly Patients With pneumonia-A Bayesian Network Meta-analysis of Randomized Control Trials. (Pubmed Central) -  Jun 8, 2021   
    We ultimately identified 34 eligible randomized controlled trials that involved 3,111 elderly participants and investigated 4 CHIs combined with Western medicine (WM) (Xiyanping injection [XYP]+WM, Yanhuning injection [YHN]+WM, Tanreqing injection [TRQ]+WM, Reduning injection [RDN]+WM), contributing 34 direct comparisons between CHIs...Our findings were based on very limited evidence and thus should be interpreted with caution. The application of the findings requires further research.
  • ||||||||||  SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
    Enrollment open, Monotherapy, Metastases:  Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov) -  May 11, 2021   
    P2,  N=104, Recruiting, 
    The application of the findings requires further research. Not yet recruiting --> Recruiting
  • ||||||||||  Xiyanping / Qingfeng, CBT-1 (tetrandrine) / CBA Pharma
    Review, Journal:  Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts. (Pubmed Central) -  Jan 26, 2021   
    The use of Chinese herbal medicines that are capable of inhibiting SARS-Cov-2 infection may help to address this immediate unmet clinical need and may be attractive to other countries that are also seeking new options for effective COVID-19 treatment. Our analyses suggest that countries outside of China should also consider protocols involving Chinese herbal medicines combat this fast-spreading viral infection.
  • ||||||||||  Xiyanping / Qingfeng
    Retrospective data, Review, Journal:  Efficacy and safety of Xiyanping for COVID-2019: A protocol for systematic review and meta-analysis. (Pubmed Central) -  Nov 26, 2020   
    Our analyses suggest that countries outside of China should also consider protocols involving Chinese herbal medicines combat this fast-spreading viral infection. Our study aims to systematically present the clinical evidence of Xiyanping in the treatment of COVID-19, which will be of guiding significance for further research and clinical practice.